HCPCS Level II code J9326 denotes the injectable oncologic agent telisotuzumab vedotin-tllv, billed per 1 mg. As a recently introduced antibody-drug conjugate for targeted cancer therapy, this code enables providers and payers to identify drug-specific utilization and manage reimbursement for infusion-based administration. Nationally, accurate use of J9326 matters for claims processing, pharmacy billing, and tracking high-cost specialty oncology therapies.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of the code's clinical context, typical sites of service, and the payer landscape. The publication presents benchmarks for utilization and reimbursement where available, outlines relevant policy considerations for coverage and prior authorization, and summarizes coding and billing nuances specific to high-cost oncologic injectables.

The report is intended for hospital billing offices, oncology practice administrators, revenue cycle professionals, and policy analysts seeking a concise reference on J9326. Data not available in the input is noted where applicable; the content focuses on the code definition, clinical setting, and payer coverage considerations at a national level.